PTN Palatin Technologies
- 2.3500
- +0.3000+14.63%
- 2.3795
- +0.0295+1.26%
Palatin Technologies News
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Palatin Techs (PTN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $17.00.
HC Wainwright & Co. : The Palatin Techs (PTN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $17.00.
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Palatin Spikes as FDA Clears Mid-stage Trial for Weight Loss Therapy
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
Palatin Techs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 760.76% HC Wainwright & Co. → $17 Reiterates Buy → Buy 02/28/2024 760.76% HC Wainwright & Co. $
Buy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment Advancements
FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By The End Of 2024
FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By T
10 Micro-Cap Healthcare Stocks Insiders Are Buying
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
By Chris Wack Palatin Technologies shares were up 27% to $2.24 after the company said it saw positive topline results for its Phase 3 pivotal clinical trial evaluating the safety and efficacy of PL96
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery.
Palatin Stock Jumps 16% on Positive Phase 3 Data for Eye Drug
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announce
Palatin Files to Sell 1.92M Shares of Common Stock for Holders
Palatin Technologies(PTN.US) Director Sells US$23,433.72 in Common Stocks
$Palatin Technologies(PTN.US)$ Director DEVEER ROBERT K JR sold 11,700 shares of Common Stocks on Mar 6, 2024 at an average price of $2.0029 for a total value of $23,433.72.Source: Announcement What i
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were retreating late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) 0.7% lower. The iShares Biotechnology ETF (IBB)
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial
Palatin Technologies (PTN) shares were down about 37% in recent Wednesday trading after the company said a late-stage trial of its dry eye drug candidate, PL9643, did not achieve statistical significa
Palatin Technologies Is Maintained at Buy by HC Wainwright & Co.
Palatin Technologies Is Maintained at Buy by HC Wainwright & Co.
Analysis
Price Target
No Data
